APOE and Alzheimer disease: Event-driven (anticipated 5 yr.), double-blind, randomized, parallel group placebo-controlled Phase 3 prevention study in cognitively normal adults susceptible for AD (APOE, TOMM40 genotypes and age). Outcome measures: Delay onset of MCI in normal participants who are at increased risk due to age and genetic risk factors.